Other Clinical Trial - Treatment of Hereditary Hemorrhagic Telangiectasia

Status Recruiting

Clinical Trial Summary

Epistaxis are present in over 90 % of patients with Rendu - Osler . They involve no significant difference 2 sexes. They often appear in childhood and adolescence and are present in three-quarters of patients at the age of 20 years. These epistaxis increasing in frequency and volume to the age of 60 in 2/3 of patients. Epistaxis are spontaneous , repetitive and recurring . They are highly variable in duration, intensity and frequency of occurrence . Some patients may have more than 40 monthly episodes with mean duration of 5 minutes of bleeding and chronic anemia and can sometimes acute anemia with transfusions need to be source. These epistaxis stigmatize patients and inevitably affect their quality of life and social skills . The various proposed ( cauterization , intra- mucosal injections, laser selective hémostatses , embolization or surgical dermoplasties ) allow for some short-term remissions . Bevacizumab is an antiangiogenic use in the treatment of colorectal cancers . It is also used in ophthalmology intravitreal to reduce vascular proliferation in glaucoma retinopathy and certain corneal neovascularization. In 2009, Prithviraj reported the use of bevacizumab injection to treat pulmonary arteriovenous malformations in a patient with Rendu - Osler . The result is doubly interesting including a saving action on epistaxis which decrease in frequency and duration. This communication prompted the authors to focus more on this medication. The product has been used in local submucosal injection intranasal laser was coupled with satisfactory results objectified by a decrease in the number of epistaxis , reducing blood transfusions and improved social lives. The use of local instillation bevacuzimab represents a way forward for the treatment of these epistaxis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Telangiectasia, Hereditary Hemorrhagic
Telangiectasis

Clinical Trial Details

NCT number	NCT02157987
Study type	Interventional
Source	University Hospital, Caen
Contact	Laetitia ROBARD, MD
Phone	33231064388
Email	robard-l@chu-caen.fr
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	December 15, 2014
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03227263` - BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).	Phase 3
Completed	`NCT00733655` - Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
Completed	`NCT00355108` - ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome	Phase 3
Completed	`NCT01507480` - The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia	Phase 1
Completed	`NCT03910244` - Pomalidomide for the Treatment of Bleeding in HHT	Phase 2
Completed	`NCT04108052` - Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient	N/A
Recruiting	`NCT04976036` - Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients	Phase 2
Completed	`NCT00684879` - Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
Completed	`NCT00004648` - Studies of Hereditary Hemorrhagic Telangiectasia	N/A
Completed	`NCT00230672` - Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
Completed	`NCT03954782` - Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.	Phase 2
Completed	`NCT02484716` - Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)	Phase 2
Recruiting	`NCT00230685` - Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
Terminated	`NCT02204371` - Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia	Phase 2
Recruiting	`NCT00230620` - Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
Completed	`NCT01408030` - North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	Phase 2
Completed	`NCT00230659` - Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia
Withdrawn	`NCT00733629` - Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia
Active, not recruiting	`NCT00230633` - Studies of White Blood Cells Derived From HHT Patients
Recruiting	`NCT05933330` - Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose — EROSB

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms